Status:
UNKNOWN
Single Injection Infromedial Peribulbar Injection in Lacrimal Duct
Lead Sponsor:
Research Institute of Ophthalmology, Egypt
Conditions:
Pain Due to Certain Specified Procedures
Eligibility:
All Genders
16-70 years
Phase:
NA
Brief Summary
infromedial injection of 3 ml local anesthetic drugs and assessing the pain during lacrimal duct intubation and probability of false tracking
Detailed Description
After entering the OR; the patient will be cannulated and fully monitored with basic monitors (pulse oximeter, NIBP \& ECG), a nasal cannula is connected to the patient to deliver oxygen. We gave the...
Eligibility Criteria
Inclusion
- adults undergoing lacrimal duct intubation surgery
- Patients' physical status by the American Association of Anesthesiology (ASA): ASA I, II, III.
- Age between 18-70, both sexes.
- Axial lengths ranging between 22-28mm.
Exclusion
- ASA IV.
- Patient age less than 18 or more than 70 years.
- Coagulation disorders (e.g. patients on warfarin (INR\<1.5)
- Communication difficulties preventing reliable assessment.
- High myopia (axial length more than 28mm) and medial staphylomas.
Key Trial Info
Start Date :
September 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04859049
Start Date
September 10 2021
End Date
November 1 2022
Last Update
September 21 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Institute of Ophthamology
Giza, Egypt, 12573
2
Research Institute of Ophthalmology
Giza, Egypt